Exploring innovations, challenges, and future horizons in parenteral drug delivery.
For this roundtable, Contract Pharma called upon thought leaders across the pharmaceutical services sector to address “3 Key Trends” impacting the CDMO industry in 2025 and beyond.
Bringing a sterile injectable product from development to commercialization requires a seamless scale-up process—one that minimizes risk, optimizes efficiency, and ensures regulatory success. In this exclusive webinar, experts from August Bioservices will discuss the critical factors that make or break a successful scale-up, sharing insights from a CDMO’s unique perspective.
CDMO leaders talk about navigating a dynamic landscape of innovation and demand.
Jenn Adams recognized in The Healthcare Technology Report, ” The Top 50 Women Leaders in Healthcare Technology of 2024″. In a rapidly changing and evolving industry, these executives are helping chart a course for an industry that is projected to hit $1 trillion within the next 10 years.
August Bioservices LLC has received $1 million in funding from the Tennessee Department of Economic and Community Development for machinery and additional staff. This is not the first or the last time the pharmaceutical company will be expanding.
August Bioservices’ VP of Operations offers his thought leadership.
Another $65 million is music to the ears of the team at August Bioservices, a contract manufacturer in Nashville.
The funding comes two months after August Bioservices completed the first stage of a $64.7 million campus expansion, which included a renovated commercial facility with sterile processing equipment and new laboratory instrumentation.
Will be used to add an additional sterile injectable filling suite to support high-speed liquid vial filling.